The three pharmaceutical companies of the real department were suspended for the reorganization

The real Medicine (600607), Chinese and Western medicine (600842) and Shanghai Medicine (600849) also announced that three companies in the actual control of Shanghai Industrial (Group) Co., Ltd. is planning a major restructuring related to the company, The relevant parties will, after the publication of this bulletin to the relevant departments for policy advice and program demonstration, so there is uncertainty about the matter.　　The shares have been suspended for five working days since June 18, upon application by three companies. Data show that the Chinese and western medicine and Shanghai Pharmaceutical Holding shareholders are Shanghai Pharmaceutical (Group) Co.　　In the first quarter of 2009, on the real medicine will contribute 40% of the company's profit Lianhua equity transfer, to obtain a pre-tax income of 536 million yuan, this move is widely regarded as the company's imminent restructuring of the precursor. Earlier, some assets and personnel changes in the country's capital have shown signs of a reorganization of the pharmaceutical industry.　　July 2008, through the free transfer of state-owned equity, Shanghai Real (Group) Co., Ltd. will Shanghai Pharmaceutical (Group) Co., Ltd. 60% of the income capsule; in December 2008, Lu Mingfang, chairman of Medicine, was appointed chairman of Shanghai Medicine. CIC Securities researcher Li Yu that the integration of pharmaceutical assets between Shanghai Industrial group and Shanghai Pharmaceutical Group will accelerate, the integration of the state-owned restructuring will not only financial restructuring, but also industrial restructuring.　　Under the premise of industrial reorganization, the possibility of the integrated platform of Shanghai state-owned medicine industry is greater. Honglu Securities Research Fellow, Shanghai Pharmaceutical Group, in addition to the above two listed companies, but also has a prescription medicine division, antibiotics Division, Chinese Medicine and Natural Medicine Division, Raw Material Medicine Division, OTC division, such as the five major division, Prescription medicine division of the Xinyi Pharmaceutical Factory and the first biochemical plant, as well as the Chinese medicine division of the Shang Pharmacy and other quality assets are not listed.